Медицинская иммунология (Dec 2016)

ROLE OF IL-6 IN EXPERIMENTAL ARTHRITIS CAUSED BY TRANSFER OF ARTHRITOGENIC ANTIBODIES

  • M. S. Drutskaya,
  • E. A. Gorshkova,
  • A. S. Zhdanova,
  • K.-S. Atretkhany,
  • V. S. Gogoleva,
  • R. V. Zvartsev,
  • A. A. Kruglov,
  • S. A. Nedospasov

DOI
https://doi.org/10.15789/1563-0625-2016-6-569-574
Journal volume & issue
Vol. 18, no. 6
pp. 569 – 574

Abstract

Read online

Interleukin-6 (IL-6) exerts important functions on immune regulation. In case of high expression, IL-6 may promote autoimmune disorders, e.g., arthritis. Systemic IL-6 blockers based on monoclonal antibodies against IL-6, or its specific receptor subunit, are already used in clinical settings, adding to a range of known biological drugs, such as, TNF blockers. Rheumatic disorders and their experimental therapy are reproducible in mice. This study revealed systemically increased levels of IL-6 in developing arthritis caused by transfer of pathogenic antibodies, as well as the effects of IL-6 neutralization by monoclonal antibodies against murine IL-6. Our results suggest a pathogenic role of the two cytokines, TNF and IL-6, in experimental arthritis induced by passive transfer of anti-collagen antibodies.

Keywords